IncyteINCY

• Phase 3INCA033989 본태성 혈소판증가증 3상 임상시작 전A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
  74%
• Phase 1포보르시티닙·룩소리티닙 피부 흡수·약동학 연구모집 중A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
  47%
• Phase 1INCB000928 골수증식질환 빈혈 단독·병용 치료 임상진행 중INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
  85%
• Phase 3INCA33890 전이성 대장암 1차 항암 병용 치료 임상모집 중A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
  39%
• Phase 3INCB123667 백금저항성 난소암 환자 치료 임상모집 중Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
  40%
• Phase 2포보르시티닙 청소년 중증 화농성 한선염 임상모집 중Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
  70%
• Phase 3만성 이식편대숙주질환 1차 치료 Axatilimab 병용 임상모집 중A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
  57%
• Phase 3Povorcitinib 결절성 양진 치료 임상모집 중A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
  41%
• Phase 2난치성 난소암 표적치료제 INCB123667 임상모집 중A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
  68%
• Phase 3INCB161734 KRAS 변이 췌장암 병용 임상모집 중A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
  66%
• Phase 2타파시타맙 자가면역 혈액질환 안전성 임상모집 중Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
  73%
• Phase 3포보르시티닙(Povorcitinib) 기존 환자 대상 연장 임상모집 중Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
  41%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.